Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BACKGROUND: NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., Fendler, W. P., Auernhammer, C. J., Spitzweg, C., Bartenstein, P., Todica, A., Ilhan, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686531/
https://www.ncbi.nlm.nih.gov/pubmed/31395036
http://dx.doi.org/10.1186/s12885-019-6000-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686531/
https://www.ncbi.nlm.nih.gov/pubmed/31395036
http://dx.doi.org/10.1186/s12885-019-6000-y

Ejemplares similares